AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Slides:

Advertisements

Similar presentations

Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.

Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Can we prevent stent restenosis after coronary stent implantation

ARTS I & II Keith D Dawkins Southampton University Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.

Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.

Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.

C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.

Department of Cardiolog Shenyang Northern Hospital

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.

Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.

ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.

David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.

The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.

Latvian Centre of Cardiology real-life registry

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

On behalf of all principal COMPARE II investigators:

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

On behalf of J. Belardi, M. Leon, L. Mauri,

FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.

Giuseppe Biondi Zoccai, MD

The American College of Cardiology Presented by Dr. Raimund Erbel

Impact of Platelet Reactivity Following Clopidogrel Administration

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

On behalf of all principal COMPARE II investigators:

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Presented at TCT 2006.

Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J

Maintenance of Long-Term Clinical Benefit with

DEScover: One-Year Clinical Results

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Ahmed A. Khattab, MD For the German Cypher Registry Investigators

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Glenn N. Levine et al. JACC 2011;58:e44-e122

The American College of Cardiology Presented by Dr. A. Abazid

Presentation transcript:

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT TM CORONARY STENT IMPLANTATION, IN REAL-WORLD CLINICAL PRACTICE. C. Graidis, G. Mamadas, D. Dimitriadis, A. Ntatsios, A.D. Maurogianni, V. Psifos, V. Karasavides, K. Stefanou, G. Spiromitros, G. Karakostas, D. Platogiannis. Cardiology Department, Euromedica-Kyanous Stavros, Thessaloníki, Greece.

Aims To evaluate the safety and efficacy of the PROMUS Element™ stent system for the treatment of patients with de novo atherosclerotic coronary artery lesions. This everolimus-eluting stent is based on a platinum chromium platform and is being evaluated in the PLATINUM clinical trial.

Materials and Methods A total of 100 consecutive patients were identified, who underwent percutaneous coronary intervention with PROMUS Element™ stent implantation between December 2009 and April The incidence of in-hospital and short-term Major Adverse Cardiac Event (death, myocardial infarction, target lesion revascularisation) rate was examined.

Baseline characteristics n100 Clinical Characteristics Mean Age (years)66 (Range: 42 to 90) Men (%)75 Diabetes Mellitus (%)19 Hypertension (%)66 Dyslipidemia (%)42 Current smokers (%)30

Indication for PCI Acute Coronary Syndrome (%) 84 Stable Angina (%)16 Angiographic characteristics Bifurcation lesions22 Total Occlusions11 Previous PCI (%)15 Previous CABG (%)7

PCI Data Total Number of Stents implanted 232 (2.32±1.19 per patient) Number of Vessels treated per patient (Average±StDev) 1.58±0.68 Number of Stents per lesion treated (Average±StDev) 1.21±0.52 Stent Diameter (mm)Mean±StDev: 2.83±0.31 / Range: 2.25 to 4 Stent Length per patient (mm)Mean±StDev: 51.6±26.2 / Range: 16 to 116 Direct Stenting (% of the cases) 40.6 Post - dilation (% of the cases)91.5

In-Hospital Clinical Outcomes Procedural success rate: 100% In-hospital MACEs: 0 Short-Term Clinical Outcomes Clinical follow-up available in all patients with a mean duration of 6.4±1.3 months (range: 5 to 9 months). 1 patient with a recent history of a large anterior MI died suddenly one month post-PCI and 1 patient died due to cerebrovascular accident. 1 patient who received a stent in the mid-LAD, developed a new critical ostial LAD lesion 8 months after the index PCI and underwent CABG. No patients required target lesion revascularisation and there were no cases of myocardial infarction.

CASE 1 Coronary Angiography Immediate Result F/U 6 months

CASE 2 Coronary Angiography Immediate Result F/U 6 months

Conclusions Our initial experience with the PROMUS Element™ coronary stent system shows that it is safe and effective with an acceptable MACE rate at short term follow-up.